Ryan Cory Maves, MD
- Professor, Infectious Diseases

Ryan Cory Maves, MD
Research Interests
- Sepsis
- Immunocompromised Host
- Global Health
- Respiratory Pathogens
- Disaster Planning
- Education
- MD, University of Washington, 1999
- Internship
- Naval Medical Center San Diego, 2000
- Residency
- Naval Medical Center San Diego, 2005
- Fellowship
- Infectious Disease, Naval Medical Center San Diego, 2007
- Critical Care, Naval Medical Center - San Diego, 2014
- Board Certifications
- American Board of Internal Medicine, Critical Care Medicine
- American Board of Internal Medicine, Infectious Disease
- American Board of Internal Medicine, Internal Medicine
- Positions
- Professor, Infectious Diseases
- Professor, Anesthesiology
- Departments and Affiliations
- Infectious Diseases
- Anesthesiology
- Office of Global Health
Research
- Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection. Richard SA, Pollett SD, Fries AC, Berjohn CM, Maves RC, Lalani T, Smith AG, Mody RM, Ganesan A, Colombo RE, Lindholm DA, Morris MJ, Huprikar N, Colombo CJ, Madar C, Jones M, Larson DT, Bazan SE, Mende K, Saunders D, Livezey J, Lanteri CA, Scher AI, Byrne C, Rusiecki J, Ewers E, Epsi NJ, Rozman JS, English C, Simons MP, Tribble DR, Agan BK, Burgess TH. JAMA Netw Open. 2023 Jan; 6(1):e2251360.
- Distinct blood inflammatory biomarker clusters stratify host phenotypes during the middle phase of COVID-19. Blair PW, Brandsma J, Chenoweth J, Richard SA, Epsi NJ, Mehta R, Striegel D, Clemens EG, Alharthi S, Lindholm DA, Maves RC, Larson DT, Mende K, Colombo RE, Ganesan A, Lalani T, Colombo CJ, Malloy AA, Snow AL, Schully KL, Lanteri C, Simons MP, Dumler JS, Tribble D, Burgess T, Pollett S, Agan BK, Clark DV. Sci Rep. 2022 Dec; 12(1):22471.
- Uses of Procalcitonin as a Biomarker in Critical Care Medicine. Maves RC, Enwezor CH. Infect Dis Clin North Am. 2022 Dec; 36(4):897-909.
- Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Potter GE, Bonnett T, Rubenstein K, Lindholm DA, Rapaka RR, Doernberg SB, Lye DC, Mularski RA, Hynes NA, Kline S, Paules CI, Wolfe CR, Frank MG, Rouphael NG, Deye GA, Sweeney DA, Colombo RE, Davey RT, Mehta AK, Whitaker JA, Castro JG, Amin AN, Colombo CJ, Levine CB, Jain MK, Maves RC, Marconi VC, Grossberg R, Hozayen S, Burgess TH, Atmar RL, Ganesan A, Gomez CA, Benson CA, Lopez de Castilla D, Ahuja N, George SL, Nayak SU, Cohen SH, Lalani T, Short WR, Erdmann N, Tomashek KM, Tebas P. Ann Intern Med. 2022 Nov;
- Nirmatrelvir Plus Ritonavir for COVID-19: The First Step Is Getting the Name Right. Wisniewski P, Berjohn CM, Maves RC. Mil Med. 2022 Nov;